Balaxi Pharmaceuticals Limited Overview
Balaxi Pharmaceuticals is a Hyderabad-headquartered, promoter-controlled, branded-generics distributor-turned-manufacturer that sells essential medicines into frontier and semi-regulated markets — principally Angola in Africa and five Central American and Caribbean markets (Guatemala, Dominican Republic, Honduras, El Salvador, Nicaragua). Its moat, as management frames it, is the combination of country-level product registrations (964 at FY26; 980 by Q1 FY27), local warehousing (38 warehouses) and on-ground expatriate-led commercial teams, now complemented by its first captive oral-solid-dosage plant at Jadcherla, Telangana, which received its manufacturing licence in May 2026 and WHO-GMP certification in August 2026. The company is small (FY26 revenue INR 270.17 crore) and currently in a profitability trough: EBITDA margin compressed from roughly 18–20% in FY22–FY24 to 4.2% in FY26, driven by a working-capital-heavy push into Angola's institutional channel, plant readiness costs and new-market spending, culminating in a CRISIL downgrade and a share-price decline of roughly 89% from its peak.
Company's own description (AR FY26)
Balaxi describes itself as a branded, IPR-driven pharmaceutical company serving frontier and semi-regulated markets across Africa and Latin America. Its operating model, in the company's words, is built around identifying product gaps, securing local registrations, maintaining availability through warehousing and distribution, and building brands where access to affordable medicines is structurally important. The FY26 annual report is themed "Affordable Access – Integrated Scale" and articulates four operating pillars: access-led market presence, a registration-led moat, manufacturing-led control (the Jadcherla plant), and distribution-led reach (warehouses, local teams and fleet). The company labels its model "produce, stock and sell" and describes a deliberate evolution from "asset light" to "asset right."
The company's articulated value chain is: market research and therapeutic-gap identification → product selection (essential, OTC, generic and branded-generic) → dossier preparation and in-country registration → manufacturing (Jadcherla) or sourcing from approved third-party manufacturers → stocking in local warehouses → sale through wholesalers, pharmacies, healthcare professionals, institutions and hospitals → brand and channel development with pharmacists and physicians.
Independent characterisation
In substance, Balaxi has historically been an importer-distributor with owned brands and owned registrations rather than a pharmaceutical manufacturer. "IPR" in Balaxi's usage refers chiefly to ownership of marketing authorisations (product registrations) and trademarks in its destination markets, not patents or proprietary molecules. Products were sourced from WHO-GMP certified contract manufacturers in India and China (and, per the AR FY26 risk table, Portugal), shipped to local subsidiaries, warehoused, and sold under the Balaxi brand umbrella. The economic value lies in (i) the time and cost of building registration portfolios in markets where registration takes 12–24 months (AR FY26), (ii) the logistics and credit capability to keep stock available in markets with fragmented distribution, and (iii) the gross-margin spread between Indian ex-factory generic costs and destination-market prices — evidenced by consolidated gross margins of 43–47% in FY24–FY26.
The FY26 transition introduces a captive manufacturing leg (Jadcherla OSD plant) intended to internalise part of the contract-manufacturing margin and improve supply control. The plant is small relative to group needs (two 37-station compression machines, three packing lines) and will be commercialised product-by-product.
A second, less-advertised feature of the model is balance-sheet intensity: inventory of around 120 days and receivables of 138 days at FY25 (CRISIL), with institutional-channel collection cycles of 180–240 days. Balaxi effectively extends trade credit and carries stock in hard-currency-scarce markets, which exposes it to currency devaluation (Angola, 2023) and counterparty payment risk.
Revenue model and mix
| Dimension | Disclosure | Source |
|---|---|---|
| Revenue model | Product sales (100% product revenue; no service, subscription or licensing revenue disclosed) | AR FY26 |
| Business lines | Pharmaceuticals (core); ancillary building hardware/construction materials (discontinuation initiated FY26); branded consumer products historically (e.g., "YAP" biscuits launched Feb 2019) | AR FY26; CRISIL; IIFL summary |
| Branded vs generic (portfolio) | Branded generics ~40%, generics ~60% (FY26 portfolio) | AR FY26 |
| Branded vs generic (Q1 FY27 sales) | 54% branded, 46% generics | Q1 FY27 investor presentation (Quartr summary) |
| Geography (FY26) | LATAM INR 111.29 crore (41% of revenue on a rupee basis); Angola and other INR 158.88 crore (derived). AR FY26 elsewhere states "Angola 52% / LATAM 48%" — internally inconsistent | AR FY26 |
| Channels | Wholesalers, pharmacies, healthcare professionals, institutional/hospital buyers (growing in Angola) | AR FY26; CRISIL Apr 2026 |
| Customer types | Private pharmacy and wholesaler trade; government and private hospitals/institutions (Angola); retail end-consumers paying out-of-pocket | AR FY26 |
| End-markets | Primary care, anti-infectives, analgesics, anti-malarials, vitamins, chronic-care generics | AR FY26 |
Value-chain position
Balaxi sits in the middle and downstream of the generic pharmaceutical value chain: it does not develop APIs or new formulations, but controls registration, import, warehousing, distribution and brand-building in destination markets. With Jadcherla, it adds finished-dosage manufacturing for selected OSD products. It competes against both large Indian exporters (which sell through local distributors or own subsidiaries) and local importers/distributors.
Strategy
Stated strategy themes (AR FY26 and investor presentations, paraphrased)
The FY26 annual report's strategy is organised around three reinforcing pillars — registration-led market access, distribution infrastructure and captive manufacturing — and the "asset light to asset right" transition. Management states it targets top-two positions in each geography, uses an Indian-expatriate leadership model combined with local hiring, and prioritises depth before scale in market entry. Earlier presentations (2020–2022) set a vision of expanding into 20 frontier markets within five years; that target has not been met (six operating markets at FY26) and is no longer emphasised.
Strategic initiatives — last 24 months
| Initiative | Description | Status (Oct 2026) | Timeline (AR FY26) |
|---|---|---|---|
| Jadcherla commercialisation | Phased, product-by-product commercial production of OSD products for Angola and LATAM | Commercial production started for initially approved products (Aug 2026) | H1 FY27 |
| WHO-GMP certification | Certification to strengthen institutional and tender credentials | Received Aug 2026, valid to Aug 2029 | FY27 (achieved) |
| Angola institutional channel normalisation | Tighter customer selection, receivable ageing and exposure limits | In progress | H1–H2 FY27 |
| LATAM expansion — Ecuador and Chile | Entry into larger, higher-spend LATAM markets | Subsidiary formed (Ecuador); expansion initiated | FY27–FY28 |
| Building-hardware discontinuation | Exit ancillary business to focus capital on pharma | Initiated FY26 | FY27 |
| Branded-share increase | Raise branded generics share (40% portfolio) for pricing and loyalty | Ongoing | Ongoing |
| Registration deepening | 49 new in FY26; 16 in Q1 FY27; 200+ pipeline | Ongoing | Ongoing |
| Digital infrastructure | SAP ERP, digitised regulatory workflows, CRM, dashboards; being "AI enabled" | Ongoing | Ongoing |
| New-market entry planning | Selective replication in new frontier markets; AR SWOT mentions South-East Asia and CIS | Planning | FY27–FY28 |
| Dubai hub capitalisation | USD 5 million (Aug 2024) and up to USD 4 million (Nov 2025) equity into Dubai WOS | Approved | — |
ESG and cost programmes
No quantified cost-reduction programme or ESG target is disclosed. CSR focuses on school construction in Hyderabad.
Medium-term targets and guidance
Balaxi provides no quantitative revenue, margin or earnings guidance. AR FY26 states management expects better operating leverage as Jadcherla scales, Angola working capital improves and LATAM grows; the Q1 FY27 presentation repeats the expectation of improvement as operating leverage strengthens. CRISIL (Apr 2026) expected FY26 revenue of ~INR 280 crore (actual 270.17) and operating margin ~5% (actual 4.2%), with debt-protection metrics recovering in FY27; its upgrade trigger is net cash accruals above INR 25 crore, and its downgrade trigger is operating margin below 5% in the coming fiscal.
Products & Services
Portfolio scale
| Metric | Value | Date | Source |
|---|---|---|---|
| Registered products (country-registrations) | 548 | Oct 2020 | NSE investor presentation |
| Registered products | 556 | May 2021 | NSE investor presentation |
| Registered products | 564 | Nov 2021 | NSE investor presentation |
| Registered products | 964 (49 added in year; 200+ filed/pipeline) | FY26 | AR FY26 |
| Registered products | 980 (16 added in Q1) | Q1 FY27 | Q1 FY27 presentation (Quartr) |
| Distinct products in catalogue | ~289 (sum of category counts in AR FY26 "Our Offerings") | FY26 | AR FY26 (analyst sum) |
"Registrations" count each product-country approval; a single molecule-strength registered in five countries counts five times. The distinct catalogue is therefore roughly 289 SKUs/products, consistent with third-party descriptions of "300+ products."
Catalogue by therapeutic category (AR FY26 "Our Offerings")
| Therapeutic category | Number of products | Typical customer | Notes |
|---|---|---|---|
| Antibiotics | 75 | Pharmacies, hospitals, institutions | Largest category; antibiotics ~41% of therapeutic mix |
| Analgesics | 57 | Pharmacies, OTC | ~14% of therapeutic mix |
| Medical devices | 32 | Pharmacies, hospitals | Product types not specified |
| Vitamins | 26 | Pharmacies, OTC | — |
| Anti-malaria | 16 | Pharmacies, institutions (Angola) | ~8% of therapeutic mix |
| Erectile dysfunction | 8 | Pharmacies | — |
| Hypertension | 7 | Pharmacies | Chronic care |
| Anti-asthma | 6 | Pharmacies | — |
| Steroids | 6 | Pharmacies, hospitals | — |
| Anti-helminthic | 5 | Pharmacies | — |
| Anti-ulcer | 5 | Pharmacies | — |
| Hygiene | 5 | Retail | — |
| Anticholinergic | 4 | Pharmacies | — |
| Dietary supplements | 4 | Retail | — |
| Diuretics | 4 | Pharmacies | — |
| Hormones | 4 | Pharmacies | — |
| Other | 4 | — | — |
| Anti-emetic | 3 | Pharmacies, hospitals | — |
| Bronchodilator | 3 | Pharmacies | — |
| Local anaesthetic | 3 | Hospitals | — |
| Anaemia | 2 | Pharmacies | — |
| Anti-diarrhoea | 2 | Pharmacies | — |
| Antihistamine | 2 | Pharmacies | — |
| Hypotension | 2 | Pharmacies | — |
| Antacid | 1 | OTC | — |
| Anti-tuberculosis | 1 | Institutions | — |
| Insect repellent | 1 | Retail | — |
| Laxative | 1 | OTC | — |
Balaxi does not publicly disclose individual brand names, specifications, launch years or pricing for its products in the sources reviewed; all products are marketed under the Balaxi corporate brand. The catalogue is therefore presented at category level, which is the most granular level publicly disclosed.
Portfolio mix
| Mix dimension | FY26 (AR, portfolio basis) | Q1 FY27 (presentation, sales basis) |
|---|---|---|
| Branded generics | 40% | 54% |
| Generics | 60% | 46% |
| Tablets | 41% | 60% (tablets) |
| Capsules | 16% | — |
| Liquids | 15% | 40% (injectables/liquids combined) |
| Injectables | 12% | — |
| Others | 16% | — |
| Antibiotics (therapeutic) | 41% | — |
| Analgesics | 14% | — |
| Anti-malarials | 8% | — |
| Others (therapeutic) | 37% | — |
The two bases are not like-for-like; the higher branded share in Q1 FY27 sales may reflect mix effects or a different definition and should not be read as a step-change without confirmation.
Manufacturing "product" — Jadcherla OSD facility
| Parameter | Detail (AR FY26) |
|---|---|
| Location | Plots S-10, S-11, S-12, Pharma SEZ, Jadcherla, Mahabubnagar, Telangana |
| Land / built-up area | 13,855 sq m / 3,373 sq m |
| Dosage forms | Oral solid dosage — tablets and capsules |
| Design standards | WHO-GMP, CDSCO, PIC/S |
| Granulation | 10 kg and 150 kg lines (wet and dry) |
| Compression | Two double-rotary 37-station machines |
| Packing | Two blister lines (PVC/Alu and Alu/Alu), one strip line |
| QC | Two HPLC units, FTIR, UV spectrophotometry, dissolution, microbiology, stability chambers |
| Utilities | HVAC, purified water, compressed air, two 200 kW DG sets |
| Status | Licence received May 2026; WHO-GMP certification August 2026 (valid to Aug 2029); commercial production commenced for initially approved products |
Non-pharma lines
Building hardware / construction materials (Angola) — being discontinued; product detail not disclosed. Branded consumer products ("YAP" biscuits, launched Feb 2019) — current status not disclosed.
Financial Narrative
All figures are consolidated, INR crore, from AR FY26 five-year snapshot and Board's Reports FY25/FY26 unless noted. Blank cells = not publicly disclosed in sources reviewed.
Income statement (chartable)
Notes: Finance costs FY22–FY24 and PBT/tax FY22–FY24 from StockAnalysis (consistent with AR where overlapping). AR FY26 reports FY22 and FY23 EPS on pre-split INR 10 face value (47.66 and 45.81); split-adjusted figures from TipRanks align with dividing by five. FY22 dividend of INR 0.50 on INR 10 face value = INR 0.10 split-adjusted; it was paid in July 2022 (FY23 cash flow) as a final dividend for FY22. FY25 revenue appears as INR 292.56 crore (AR) and INR 294.92 crore (CRISIL "operating income"); total income was INR 288.84 crore after negative other income of INR 3.72 crore (FX loss).
Margins and growth (chartable)
Revenue CAGR: FY22–FY26 (4 years) = −0.8%; FY21–FY26 (5 years, FY21 base ~INR 231 crore per Screener) = +3.2%. Screener's machine-generated five-year sales growth figure (~6%) uses a different window.
Balance sheet (chartable)
Notes: Total assets FY22–FY25 from TipRanks (labelled by calendar year on that site; mapped to fiscal years by matching equity). Cash and equivalents, short-/long-term debt split, net debt, goodwill and intangibles are not publicly disclosed in the sources reviewed. CRISIL's adjusted net worth for FY25 (INR 204.9 crore) differs from the AR figure (INR 231.74 crore), likely due to analytical adjustments. FY26 equity rose by INR 17.3 crore despite PAT of only INR 1.42 crore, implying a material positive other-comprehensive-income item (most plausibly foreign-currency translation); the composition is not disclosed in sources reviewed. Book value per share = equity / 5.52 crore shares (FY22–FY23 approximate, as share count was lower before warrant conversions).
Cash flow (chartable)
Notes: Cash-flow statement line items are not publicly disclosed in the sources reviewed. Dividend paid FY23 is an analyst estimate (INR 0.50 × ~1.0 crore pre-split shares). Preferential-issue receipts by year are analyst allocations of the INR 47.57 crore total: INR 1.10 crore equity plus 25% warrant upfront (INR 12.06 crore) in Oct 2022; INR 6.96 crore of conversions to Sep 2023 per the SoDV filing (assigned FY24, although part may fall in FY23); remaining conversions largely Jan–Apr 2024 (split between FY24 and FY25 — the allocation shown is indicative only). The company confirms proceeds were fully utilised by Q4 FY26. A 2021 Quartr summary noted that working-capital growth constrained FY21 operating cash flow — a pattern consistent with the subsequent receivable build-up.
Ratios (chartable; analyst calculations from figures above)
Notes: ROIC for FY22–FY24 uses StockAnalysis operating income (49.72, 54.81, 44.64) as EBIT proxy; FY25–FY26 use AR EBITDA less D&A. Invested capital = equity + debt. Net debt/EBITDA cannot be computed (cash not disclosed). CRISIL's figures differ: interest coverage 16.35x (FY24) and 8.64x (FY25); adjusted gearing 0.10x (FY24) and 0.25x (FY25); current ratio 4.52x (FY25). Cash conversion cycle: CRISIL reports inventory of ~120 days and receivables of 138 days at FY25 (gross current assets 295 days); payable days are not disclosed, so a full CCC cannot be computed. The AR FY26 MD&A ratio table (current ratio 1.27, ROE 47%, inventory turnover 124,455x, net profit ratio 6.37%) appears to relate to the standalone entity and contains internal inconsistencies (e.g., ROE 47% alongside return on net worth 3.95%); it is not relied upon.
Quarterly trajectory (chartable)
Notes: Q1 FY26 and Q1 FY27 as reported (NSE outcome 5 Aug 2026; an alternate Q1 FY26 figure of INR 70.74 crore appears in one secondary source). Q2–Q4 FY26 derived from cumulative H1 (INR 126.92 crore, IIFL), 9M (INR 199.45 crore, CRISIL) and full-year (AR) disclosures. Q1 FY27 gross margin 46.5% (+241 bps YoY); employee costs INR 11.36 crore vs INR 8.41 crore (+35%); PBT INR 2.09 crore; effective tax 37.8%; basic EPS INR 0.24. Standalone Q1 FY27: revenue INR 15.58 crore, net loss INR 1.25 crore, attributed to Jadcherla depreciation and staffing.
Commentary on trends, inflections and drivers
Revenue. The five-year revenue line is essentially flat with two large swings. FY23's peak (INR 336 crore) included favourable Angolan exchange effects; management noted in the Q1 FY23 call that extra exchange-rate profit from Angola would not recur. FY24's 28% contraction followed the kwanza devaluation, which shrank rupee-translated Angolan sales and forced pricing resets. FY25's 21% rebound came from Angolan demand recovery and new institutional business (CRISIL). FY26's 7.7% decline reflects a deliberate slowdown of the Angolan institutional channel as receivables ballooned, plus the hardware wind-down. Q1 FY27's 14% YoY growth is the first sign of reacceleration but off a weak base.
Gross margin vs EBITDA margin divergence. The single most important analytical observation is that gross margin has been stable to improving (44.2% in FY26, 46.5% in Q1 FY27) while EBITDA margin collapsed from 18.3% (FY24) to 4.2% (FY26). The compression is therefore entirely below gross profit: selling, general and administrative costs rose from INR 65.7 crore (FY24) to INR 89.4 crore (FY25) to INR 110.8 crore (FY26) per StockAnalysis — a 69% increase in two years against flat revenue. CRISIL attributes this to promotional and marketing spend to penetrate institutional sales; AR FY26 adds Jadcherla readiness costs, regulatory/quality-system investment and new-market build-out. This is an operating-leverage problem, not a pricing problem, which is the basis of the bull case.
Earnings quality. PAT has been volatile and FX-sensitive: other income swung from +INR 2.82 crore (FY26) to −INR 3.72 crore (FY25, FX loss of ~INR 6.1 crore per StockAnalysis). The FY26 effective tax rate of 73% indicates taxable profits in some jurisdictions offset by losses elsewhere. FY22–FY23 earnings had low effective tax rates (13–19%), consistent with profits booked in the UAE hub.
Balance sheet. Net working capital has grown from INR 78 crore (FY22) to INR 189 crore (FY26) — 70% of revenue — absorbing almost all equity raised and retained. Debt has risen 16-fold since FY22 (INR 3.6 crore to INR 57.7 crore), though leverage remains modest at 0.23x equity. The financial risk is less about solvency and more about the collectability of Angolan institutional receivables and the cash generation of the business: CRISIL expected net cash accruals of only ~INR 4 crore in FY26.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Group Entities
| Entity | Jurisdiction | Relationship | Function | Source |
|---|---|---|---|---|
Balaxi Pharmaceuticals Limited | India | Parent (listed) | Holding, sourcing, export, Jadcherla manufacturing | AR FY26 |
Balaxi Global FZCO (formerly Balaxi Global DMCC; renamed 2 May 2025) | Dubai, UAE | Wholly-owned subsidiary | International distribution hub; holding company for operating subsidiaries | AR FY26 |
Balaxi Healthcare Ecuador S.A.S. | Ecuador | Wholly-owned subsidiary (direct) | Expansion vehicle (nascent) | AR FY26 |
Balaxi Healthcare Guatemala, S.A. | Guatemala | Step-down WOS | Local distribution; central/WHO-GMP certified warehouse | AR FY26 |
Balaxi Healthcare Dominicana, S.R.L. | Dominican Republic | Step-down WOS | Local distribution | AR FY26 |
Balaxi Healthcare Honduras, S. de R.L. de C.V. | Honduras | Step-down WOS | Local distribution | AR FY26 |
Balaxi Healthcare El Salvador S.A. de C.V. | El Salvador | Step-down WOS | Local distribution | AR FY26 |
Balaxi Healthcare Angola | Angola | Step-down WOS | Largest market; retail and institutional distribution | AR FY26 |
Balaxi Healthcare Nicaragua | Nicaragua | Step-down WOS (from 1 Apr 2025) | Nascent market | AR FY26 |
Balaxi Healthcare Centrafrique SARL | Central African Republic | Struck off 10 Apr 2025 | Ceased | AR FY26 |
Balaxi Healthcare Chile | Chile | Listed in CRISIL consolidation (Nov 2024 onward) but not in AR FY26 subsidiary list — discrepancy | Targeted expansion | CRISIL; AR FY26 |
Business Lines
| Business line (historical definition) | Contents | Status | Source |
|---|---|---|---|
Pharmaceuticals | Branded generics, generics, OTC, medical devices across ~28 therapeutic categories | Core | AR FY26; NSE presentation Q2 FY22 |
Ancillary — building hardware / construction materials | Branded construction-related materials sold in Angola | Discontinuation initiated FY26 | AR FY26; CRISIL |
Branded consumer products | FMCG (e.g., "YAP" biscuits from 2019) | Not separately referenced in AR FY26; status not disclosed | IIFL summary |
Revenue by Segment and Revenue by Segment (%)
| Segment / Region | FY24 | FY25 | FY26 |
|---|---|---|---|
Consolidated revenue (INR Cr) | 241.29 | 292.56 | 270.17 |
LATAM revenue (INR Cr) | — | 100.26 | 111.29 |
Angola and other revenue (INR Cr) | — | 192.30 | 158.88 |
LATAM share of revenue (%) | — | 34.3 | 41.2 |
Angola and other share of revenue (%) | — | 65.7 | 58.8 |
Income Statement and Margin Analysis (%)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Revenue from operations (INR Cr) | 279.39 | 336.43 | 241.29 | 292.56 | 270.17 |
Revenue growth YoY (%) | 20.9 | 20.4 | -28.3 | 21.2 | -7.7 |
Gross profit (INR Cr) | 83.79 | 134.01 | 112.61 | 126.86 | 119.30 |
EBITDA (INR Cr) | 55.18 | 59.17 | 44.08 | 33.50 | 11.35 |
Depreciation and amortisation (INR Cr) | — | — | — | 1.89 | 2.15 |
EBIT (INR Cr) | — | — | — | 31.61 | 9.20 |
Finance costs (INR Cr) | 0.14 | 0.50 | 1.68 | 2.93 | 3.90 |
Exceptional items (INR Cr) | 0 | 0 | -38.29 | 0 | 0 |
Profit before tax (INR Cr) | 54.52 | 56.92 | 2.02 | 28.67 | 5.29 |
Tax expense (INR Cr) | 6.87 | 10.96 | 4.40 | 3.60 | 3.88 |
Net income / PAT (INR Cr) | 47.66 | 45.96 | -2.39 | 25.07 | 1.42 |
Basic EPS, split-adjusted (INR) | 9.53 | 9.16 | -0.46 | 4.54 | 0.26 |
Diluted EPS, split-adjusted (INR) | 9.53 | 9.08 | -0.46 | 4.54 | 0.26 |
Dividend per share, split-adjusted (INR) | 0.10 | 0 | 0 | 0 | 0 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansMargin Analysis (%)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Gross margin (%) | 30.0 | 39.8 | 46.7 | 43.4 | 44.2 |
EBITDA margin (%) | 19.7 | 17.6 | 18.3 | 11.5 | 4.2 |
EBIT margin (%) | — | — | — | 10.8 | 3.4 |
PBT margin (%) | 19.5 | 16.9 | 0.8 | 9.8 | 2.0 |
Net margin (%) | 17.1 | 13.7 | -1.0 | 8.6 | 0.5 |
Effective tax rate (%) | 12.6 | 19.3 | 217.8 | 12.6 | 73.3 |
Balance Sheet and Per-Share Data
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Total assets (INR Cr) | 176.0 | 240.0 | 258.0 | 310.0 | — |
Current assets (INR Cr) | 141.00 | 193.51 | 210.17 | 242.77 | 251.43 |
Current liabilities (INR Cr) | 63.27 | 53.13 | 54.20 | 54.53 | 62.16 |
Net working capital (INR Cr) | 77.74 | 140.38 | 155.97 | 188.23 | 189.27 |
Total debt incl. leases (INR Cr) | 3.64 | 13.31 | 19.40 | 53.43 | 57.65 |
Total equity / net worth (INR Cr) | 113.16 | 182.88 | 201.27 | 231.74 | 249.08 |
Book value per share, split-adjusted (INR) | 22.6 | 33.1 | 36.5 | 42.0 | 45.1 |
Dividends & Capital Returns
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Dividends paid (INR Cr) | 0 | 0.5 | 0 | 0 | 0 |
Buybacks (INR Cr) | 0 | 0 | 0 | 0 | 0 |
Equity raised via preferential issue (INR Cr) | 0 | 13.17 | 6.95 | 27.45 | 0 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Ratio | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
ROE on average equity (%) | 52.9 | 31.1 | -1.2 | 11.6 | 0.6 |
ROA on closing assets (%) | 27.1 | 19.2 | -0.9 | 8.1 | — |
ROIC, notional 25% tax (%) | 31.9 | 21.0 | 15.2 | 8.3 | 2.2 |
Current ratio (x) | 2.23 | 3.64 | 3.88 | 4.45 | 4.04 |
Debt to equity (x) | 0.03 | 0.07 | 0.10 | 0.23 | 0.23 |
Gross debt to EBITDA (x) | 0.07 | 0.22 | 0.44 | 1.59 | 5.08 |
Interest coverage, EBITDA/finance cost (x) | 388.6 | 118.3 | 26.2 | 11.4 | 2.9 |
Asset turnover (x) | 1.59 | 1.40 | 0.94 | 0.94 | — |
Income Statement
| Metric | Q1FY26 | Q2FY26 | Q3FY26 | Q4FY26 | Q1FY27 |
|---|---|---|---|---|---|
Revenue (INR Cr) | 70.71 | 56.21 | 72.53 | 70.72 | 80.68 |
PAT (INR Cr) | 0.29 | 0.21 | 0.30 | 0.62 | 1.30 |
Revenue by Region and Region Margins & Growth (%)
| Region | FY2025 | FY2026 |
|---|---|---|
LATAM revenue (INR Cr) | 100.26 | 111.29 |
Angola and other revenue (INR Cr) | 192.30 | 158.88 |
LATAM growth YoY (%) | — | 11.0 |
Angola and other growth YoY (%) | — | -17.4 |
Valuation Snapshot
| Metric | Value | As of | Source |
|---|---|---|---|
Latest verified price (INR) | 23.39 | 14 Sep 2026 | Anand Rathi |
52-week high / low (INR) | 47.71 / 15.20 | Sep 2026 | Anand Rathi |
1-year return (%) | -48.4 | 14 Sep 2026 | Anand Rathi |
3-year return (%) | -74.6 | 14 Sep 2026 | Anand Rathi |
5-year high, split-adjusted (INR) | 216.04 | as of Mar 2025 data | Equentis |
Drawdown from 5-year high to latest (%) | -89 | Analyst calc | — |
Preferential issue price, split-adjusted (INR) | 90.20 (INR 451 / 5) | 2022–2024 | NSE filings |
Valuation Multiples
| Multiple | Balaxi | Basis |
|---|---|---|
P/E (TTM) | ~53x | TTM PAT INR 2.43 crore (FY26 1.42 + Q1 FY27 1.30 − Q1 FY26 0.29) |
P/E (FY26) | ~91x | FY26 PAT INR 1.42 crore |
P/B | ~0.52x | FY26 equity INR 249.08 crore |
EV/Sales (TTM) | ≤0.67x | EV ≈ INR 186.7 crore (market cap + gross debt; cash not netted as not disclosed); TTM revenue INR 280.1 crore |
EV/EBITDA (FY26) | ≤16.4x | FY26 EBITDA INR 11.35 crore |
Caplin Point P/E (reference) | ~31x | INR 2,623 (27 Jul 2026) / FY26 EPS INR 84.36 |
Per-Share Data
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Dividend per share, split-adjusted (INR) | 0.10 | 0 | 0 | 0 | 0 |
Shares outstanding, split-adjusted (crore) | 5.00 | 5.12 | 5.45 | 5.52 | 5.52 |
Analyst Ratings & Targets
| Date | Agency | Rating / outlook | Facility | Key reasoning |
|---|---|---|---|---|
7 Sep 2022 | CRISIL | BBB+ / Stable (assigned) | INR 50 crore fund-based | Established Angola/LATAM position |
14 Aug 2023 | CRISIL | BBB+ / Negative | INR 50 crore | Kwanza devaluation loss |
5 Nov 2024 | CRISIL | BBB+ / Stable | — | FY24 recovery |
13 Nov 2025 | CRISIL | BBB+ / Negative | INR 35 crore | Profitability pressure |
1 Apr 2026 | CRISIL | BBB / Stable (downgrade) | INR 35 crore working capital (Yes Bank) | Marketing spend for institutional channel; ~5% margin; stretched working capital |
Analyst Conclusions
Management guidance
No numerical guidance. Management's stated FY27 priorities: Jadcherla commercial production (H1 FY27), Angola institutional channel normalisation (H1–H2 FY27), hardware discontinuation (FY27), WHO-GMP certification (achieved Aug 2026), Ecuador/Chile expansion and new-market planning (FY27–FY28), and continued branded-share growth. CRISIL expects debt-protection metrics to recover in FY27.
Consensus growth expectations
None available (no coverage).
Bull case (grounded in data)
-
Operating leverage on an intact gross margin. Gross margin is 44–47% and improving; the margin collapse is in opex, which rose ~INR 45 crore in two years. If revenue grows to the FY23 level (~INR 336 crore) with opex held near FY26 levels, EBITDA could exceed INR 35 crore, and at FY24-like cost intensity, approach INR 50–60 crore — against a market capitalisation of ~INR 129 crore.
-
Assets below book with a now-operational plant. At ~0.5x book, investors are paying roughly half of reported equity for a business with 980 registrations, 38 warehouses and a licensed WHO-GMP plant — the most capital-intensive phase is complete and the preferential proceeds are fully deployed.
-
Early recovery signals. Q1 FY27 revenue grew 14% YoY to INR 80.68 crore, the highest quarterly revenue in at least five quarters; PAT more than quadrupled; gross margin expanded 241 bps; WHO-GMP certification followed within weeks.
Bear case (grounded in data)
-
Receivables risk is the real issue. Net working capital of INR 189 crore is ~76% of equity; Angolan institutional collections run 180–240 days. Any impairment would erode book value — which explains the sub-book valuation — and CRISIL's downgrade trigger (operating margin <5%) was breached in FY26.
-
Structural cost base and weak returns. ROE has averaged roughly 4% over FY24–FY26; Q1 FY27 annualised ROE is ~2%. Employee costs grew 35% YoY in Q1 FY27 — faster than revenue — as Jadcherla adds fixed costs before volumes arrive.
-
Governance and disclosure discount. Combined promoter Chair/MD, material related-party transactions, history of acquiring promoter-group entities, CS turnover, an NSE fine and an NSE results query, and internally inconsistent geographic data — alongside the complete exit of foreign institutions — argue the discount may persist regardless of operating improvement.
Key catalysts and monitorables (next 12 months)
| Catalyst / monitorable | Why it matters | Timing |
|---|---|---|
| Q2 FY27 results | Confirms or refutes Q1 recovery; watch EBITDA margin vs 5% CRISIL threshold | Late Oct / Nov 2026 |
| Receivable days and any provisioning | Core balance-sheet risk | Each half-year balance sheet (Sep 2026, Mar 2027) |
| Jadcherla utilisation and product approvals | Margin-accretion thesis; additional products pending approval | FY27 |
| Angola FX and macro | Devaluation risk; inflation trajectory | Ongoing |
| LATAM growth rate and Ecuador/Chile first revenues | Diversification away from Angola | FY27–FY28 |
| Hardware wind-down completion | Cleaner pharma-only P&L | FY27 |
| CRISIL annual review | Further downgrade vs stabilisation | ~Q4 FY27 |
| Cash-flow disclosure (FY27 annual report) | Operating cash conversion | Mid-2027 |
| Shareholding changes (FII/DII re-entry, promoter buying) | Sentiment signal | Quarterly |
Analyst verdict
Balaxi Pharmaceuticals is a small, promoter-controlled frontier-market pharma distributor at the most fragile point in its transition to an integrated manufacturer. The underlying franchise is real: nearly a thousand country registrations, a physical distribution network in markets few competitors serve directly, and gross margins in the mid-40s that have held up through currency shocks and channel turmoil. The capital project is done — the Jadcherla plant is licensed and WHO-GMP certified — and the market values the whole enterprise at roughly half its stated book equity.
However, the investment case rests almost entirely on the quality of that book equity, and the evidence there is uncomfortable. Working capital absorbs about 70% of revenue; the Angolan institutional channel that drove FY25's recovery has since become the primary drag, with 180–240-day collection cycles; and the company has not disclosed cash-flow details in the sources reviewed that would allow investors to judge cash conversion. Profitability has fallen from an EBITDA margin near 18% to just over 4% in two years, primarily on costs management chose to incur. CRISIL's downgrade, the exit of foreign institutions and reporting inconsistencies all point the same way.
The asymmetric outcome is clear in principle: if management can re-impose cost discipline, collect Angolan receivables without write-downs, and load the new plant, earnings could rebound several-fold off a tiny base, and a re-rating toward book value alone would roughly double the equity. The probability of that outcome, however, is not yet evidenced by more than one quarter of data. On balance, Balaxi is best characterised as a high-risk special situation, not an investable compounder: the stock is a call option on working-capital normalisation in Angola. The decisive monitorables are receivable days, provisioning and EBITDA margin in the next two reported half-years; until those turn convincingly, the governance and balance-sheet discount is justified.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Board of Directors
| Name | Role | Category | Background (per AR FY26) | Committee roles |
|---|---|---|---|---|
Ashish Maheshwari (DIN 01575984) | Chairman and Managing Director | Executive, promoter | Founder; first-generation entrepreneur; Chartered Accountant; ~two decades in pharma (CRISIL); began supplying white-labelled formulations to importers | Member, Audit; Chair, Risk Management; Member, CSR |
Minoshi Maheshwari (DIN 01575975) | Non-Executive Director | Non-executive, promoter | Co-founder; organisational and CSR leadership; reappointed by rotation at 82nd AGM (Aug 2025); retiring by rotation again at 83rd AGM | Member, NRC; Member, SRC; Chair, CSR |
Kunal Mahendra Bhakta | Independent Director | Independent | Chartered Accountant; capital markets, fund management, investor relations, transactions | Chair, Audit; Chair, NRC; Chair, SRC |
Gandhi Gamji | Independent Director | Independent | International trade across Africa and GCC; speciality chemicals | Member of Audit, NRC, SRC, Risk, CSR |
Mangina Srinivas Rao | Independent Director | Independent | Strategy, project leadership, governance | Member, Audit |
Akshita Ostwal (formerly Surana; DIN 10026552) | Independent Director | Independent | Practising company secretary, trademark agent, corporate law and IPR | — |
Executive Leadership Team
| Name | Title | Tenure / notes | Education / prior roles |
|---|---|---|---|
Ashish Maheshwari | Managing Director | Since Balaxi takeover of listed entity (2017) | CA |
Amol Mantri | Chief Financial Officer | With Balaxi Group since 2012 | CA; US CPA |
Pranav Maheshwari | Senior Vice President — Business Development (KMP) | Leads LATAM strategy; promoter family | BBA and Economics, Emory University |
Paridhi Maheshwari | Head — Alternate Channels | Consumer-products portfolio; promoter family (relationship implied by surname; not confirmed) | MBA, London Business School |
Aman Purohit | Company Secretary and Compliance Officer | Appointed 25 Mar 2026 | — |
Mohith Kumar Khandelwal | Former Company Secretary | Resigned 29 Jan 2026 (Nodal Officer from 6 Nov 2024) | — |
Udayan Shukla | Former Company Secretary | Signed filings in 2022 | FCS |
Board & Management Changes
| Date | Change | Context |
|---|---|---|
5 Sep 2024 | Akshita Surana (now Ostwal) appointed Independent Director (postal ballot 6 Nov 2024) | Board refresh |
29 Jan 2026 | CS Mohith Kumar Khandelwal resigns | Second CS change in roughly four years |
25 Mar 2026 | Aman Purohit appointed CS | Two-month vacancy in compliance officer role during a downgrade period |
Shareholding Trend
| Holder category | Jun 2022 | Mar 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
Promoter and group (%) | 72.86 | 66.86 | 65.99 | 65.99 | 65.99 | 65.99 | 65.99 | 65.99 |
Foreign institutions (%) | 19.00 | 17.21 | 16.02 | 8.87 | 3.50 | 1.74 | 0.00 | 0.00 |
Domestic institutions (%) | 0.03 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 2.56 | 2.56 |
Public / retail and others (%) | 8.11 | 15.91 | 17.96 | 25.12 | 30.49 | 32.24 | 31.45 | 31.45 |
Competitive Landscape
Key Competitors
| Competitor | Overlap with Balaxi | FY26 revenue (INR Cr) | Positioning vs Balaxi | Source |
|---|---|---|---|---|
Caplin Point Laboratories | Central America and Caribbean branded generics; Francophone Africa; owned distribution | 2,187.19 | Closest model analogue; ~8x Balaxi's revenue; debt-free; vertically integrated with US-regulated sterile plants | Company results May 2026 |
Bliss GVS Pharma | Sub-Saharan Africa (anti-malarials, suppositories) | 927.1 (operating revenue) | Africa-focused manufacturer-exporter; niche dosage-form leadership | StockAnalysis; IIFL |
Lincoln Pharmaceuticals | Exports of anti-infectives and other formulations to Africa/LATAM | 704.48 (total income) | Manufacturer-exporter with domestic business | DSIJ May 2026 |
Cipla | Africa (incl. Angola) branded generics and tenders | Not compiled | Scale player with institutional/tender strength | — |
Sun Pharmaceutical Industries | LATAM and Africa emerging-markets generics | Not compiled | Global scale; different tier | — |
Dr. Reddy's Laboratories | LATAM, Africa emerging markets | Not compiled | Global scale; different tier | — |
Glenmark Pharmaceuticals | LATAM, Africa | Not compiled | Branded generics in emerging markets | — |
Torrent Pharmaceuticals | Latin America (Brazil, Mexico) | Not compiled | Larger LATAM markets Balaxi does not serve | — |
Ajanta Pharma | Africa branded generics | Not compiled | Strong Africa branded franchise | — |
Local importers and distributors in Angola and Central America | Same channels | — | Price competitors; relationship-driven | — |
Chinese generic exporters | Low-price generics in Africa | — | Price pressure in commodity generics | — |
“—” = not publicly disclosed.
Peer Comparison FY2026
| Metric | Balaxi | Caplin Point | Bliss GVS | Lincoln Pharma |
|---|---|---|---|---|
Revenue (INR Cr) | 270.17 | 2,187.19 | 927.1 | 704.48 |
Revenue growth YoY (%) | -7.7 | 12.9 | 14.5 | 9.1 |
Gross margin (%) | 44.2 | 60.4 | 51.7 | — |
EBITDA / operating margin (%) | 4.2 | 38.1 | 14.1 | — |
Net margin (%) | 0.5 | 29.7 | — | 12.5 |
R&D (% of revenue) | — | 4.6 | — | — |



